Israeli Biotech Company Forges Immunotherapy Collaboration with Hadassah

Wednesday, Nov 2 2016

Vaxil Biotherapeutics Israel has signed an immunotherapy collaboration agreement with the Hadassah Medical Organization, intended to enhance the Company's immunotherapy platform, including its lead product, Immucin™. 

"I am a strong believer in Vaxil's immunotherapy platform,” relates Prof. Michael Shapira, who is spearheading the collaboration and joining Vaxil’s Scientific Advisory Board. “I have spent years following Immucin's progress, and have been fortunate to witness the promising potential both in cancer patients and in the laboratory. Hadassah is excited to be embarking on this collaboration and partnering with Vaxil's scientific team." 

Through this collaboration, Hadassah cancer patients and healthy volunteers will provide tumor samples which will be analyzed in conjunction with Vaxil's immune therapies. They will also be used in Vaxil’s investigation of potential combination therapies. The company notes that Immucin has the potential to be a very strong immunotherapy, whether as a stand-alone treatment or possibly in combination with other products.

The Vaxil and Hadassah scientists will further examine the nature of immune response to its immunotherapy in hematological patients, specifically those that are in remission from multiple myeloma and leukemia. Investigations and analysis will take place primarily at Vaxil's laboratory, using the company's fluorescence-activated cell sorting machine and other facilities. Immucin has already completed a successful Phase-I/II clinical trial, under the direction of Prof. Shapira, and will now be positioned toward a larger Phase II trial. The previous trial demonstrated the safety of Immucin and established its potential to elicit a novel specific cellular response against a highly prominent cancer target entitled MUC1-SP--a target that is present on 90 percent of all human cancers, but has proven elusive in terms of optimal treatment protocol.

This Vaxil-Hadassah partnership will investigate Immucin’s mode of action and, in turn, create an optimal design for its next clinical trial, to be launched in 2017. Learn more about immunotherapy and Immucin at https://www.youtube.com/watch?v=XhEwj6Ue13s


No comments yet.
First Name
Enter this word:

Related Stories


Wednesday, Mar 22 2017

Cypriot Health Minister Helps Save Israeli Patient

Whether it was a newborn baby with a severe heart defect or a pregnant woman with an unusual ectopic pregnancy, the Hadassah Medical Organization has been known to save the lives of Cypriot patients by helicoptering them to its hospital for complex emergency treatments. Recently, however, it was the Cypriot Health Minister who helped save the life of an Israeli patient.


Wednesday, Mar 22 2017

Top-Tier Turkish Journalists Receive Inside View of Hadassah Hospital

A delegation of top-tier Turkish journalists, accompanied by representatives from the Israel Foreign Ministry, visited Hadassah Hospital Ein Kerem this month, marking the first time a high-level Turkish delegation has come to Israel since the new reconciliation agreement was signed between Israel and Turkey.


Wednesday, Mar 22 2017

Marathon Runner Pays Tribute to Hadassah Medical Team

After successfully running in the 2017 Jerusalem Marathon, Gil Troy pays tribute to Prof. Meir Liebergall, Director of the Hadassah Medical Organization’s Orthopedic Surgery Department, and his medical team, who made this run possible.


Wednesday, Mar 22 2017

Reversing the Odds with Technology and Expertise

It could be a young patient with a virulent flu. Or a man having a severe asthma attack. Or a pregnant woman with a complication of pregnancy.


Donation Questions


(800) 928-0685

Membership Questions


(800) 664-5646

Missions Department


(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005


More ›

Show More